The International Journal of Neuropsychopharmacology
August 1, 2025
Bernard Lerer, Michal Brownstien, Mitchell A. Lazar et al.
Abstract Background Obsessive-compulsive disorder (OCD) is associated with significant personal suffering and functional impairment. At least a third of OCD patients do not respond to conventional treatments. There is a substantial anecdotal literature suggesting that psychedelic agents, specifically psilocybin and psilocybin-containing psychedelic mushroom extract (PME), may be therapeutic in...
International Journal of Neuropsychopharmacology
August 1, 2025
Bernard Lerer, Peretz Golding, Michal Brownstien et al.
Abstract Background We have designed a novel psychedelic-derived compound (HBL20017) characterized by high functional efficacy at 5-HT2A, 5-HT1A, and 5-HT2C receptors. We assessed its hallucinogenic properties and its potential for OCD treatment on the marble burying test (MBT) and in mice homozygous for deletion of the Synapse Associated Protein 3 (SAPAP3) gene. These mice manifest severe,...
The International Journal of Neuropsychopharmacology
March 29, 2025
Michal Lazar, Michal Brownstien, Alexander Botvinnik et al.
3 citations
Abstract Background SAPAP3-knockout (SAPAP3-KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessive-compulsive disorder (OCD). Given that anxiety often precedes OCD diagnosis in humans, this study investigated whether juvenile SAPAP3-KO mice exhibit anxiety-like behaviors before developing the self-grooming phenotype, and whether such behaviors...
Molecular Psychiatry
October 11, 2024
Michal Brownstien, Michal Lazar, Alexander Botvinnik et al.
23 citations
Abstract Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, tic-like head-body twitches...
International Journal of Molecular Sciences
November 16, 2022
Orr Shahar, Alexander Botvinnik, Noam Esh-Zuntz et al.
60 citations
There is increasing interest in the therapeutic potential of psilocybin. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP) and psilocybin induce a characteristic 5-HT2A receptor (5-HT2AR)-mediated head twitch response (HTR), which is correlated with the human psychedelic trip. We examined the role of other serotonergic receptors and the trace amine -associated receptor 1 (TAAR1)...